124 related articles for article (PubMed ID: 23886112)
1. Inhibition of IL-17 as a pharmacological approach for IBD.
Fitzpatrick LR
Int Rev Immunol; 2013; 32(5-6):544-55. PubMed ID: 23886112
[TBL] [Abstract][Full Text] [Related]
2. New drugs on the horizon for IBD.
Sands BE
Dig Dis; 2014; 32 Suppl 1():74-81. PubMed ID: 25531356
[TBL] [Abstract][Full Text] [Related]
3. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.
Verstockt B; Van Assche G; Vermeire S; Ferrante M
Expert Opin Biol Ther; 2017 Jan; 17(1):31-47. PubMed ID: 27817215
[TBL] [Abstract][Full Text] [Related]
4. Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis.
Fitzpatrick LR
Int J Inflam; 2012; 2012():389404. PubMed ID: 22506136
[TBL] [Abstract][Full Text] [Related]
5. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?
Zhang Z; Hinrichs DJ; Lu H; Chen H; Zhong W; Kolls JK
Int Immunopharmacol; 2007 Apr; 7(4):409-16. PubMed ID: 17321463
[TBL] [Abstract][Full Text] [Related]
6. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
[TBL] [Abstract][Full Text] [Related]
7. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory mechanisms of bioactive milk proteins in the intestine of newborns.
Chatterton DE; Nguyen DN; Bering SB; Sangild PT
Int J Biochem Cell Biol; 2013 Aug; 45(8):1730-47. PubMed ID: 23660296
[TBL] [Abstract][Full Text] [Related]
9. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
Nakase H; Okazaki K; Tabata Y; Chiba T
J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
[TBL] [Abstract][Full Text] [Related]
10. Effect of IL-17A blockade with secukinumab in autoimmune diseases.
Patel DD; Lee DM; Kolbinger F; Antoni C
Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii116-23. PubMed ID: 23253932
[TBL] [Abstract][Full Text] [Related]
11. Th17 cytokines in inflammatory bowel diseases: discerning the good from the bad.
Troncone E; Marafini I; Pallone F; Monteleone G
Int Rev Immunol; 2013; 32(5-6):526-33. PubMed ID: 24041379
[TBL] [Abstract][Full Text] [Related]
12. Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis.
Mencarelli A; Distrutti E; Renga B; Cipriani S; Palladino G; Booth C; Tudor G; Guse JH; Hahn U; Burnet M; Fiorucci S
Eur J Pharmacol; 2011 Aug; 665(1-3):29-39. PubMed ID: 21554873
[TBL] [Abstract][Full Text] [Related]
13. Review of natural products actions on cytokines in inflammatory bowel disease.
Hur SJ; Kang SH; Jung HS; Kim SC; Jeon HS; Kim IH; Lee JD
Nutr Res; 2012 Nov; 32(11):801-16. PubMed ID: 23176791
[TBL] [Abstract][Full Text] [Related]
14. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F.
Leppkes M; Becker C; Ivanov II; Hirth S; Wirtz S; Neufert C; Pouly S; Murphy AJ; Valenzuela DM; Yancopoulos GD; Becher B; Littman DR; Neurath MF
Gastroenterology; 2009 Jan; 136(1):257-67. PubMed ID: 18992745
[TBL] [Abstract][Full Text] [Related]
15. Antagonistic RNA aptamer specific to a heterodimeric form of human interleukin-17A/F.
Adachi H; Ishiguro A; Hamada M; Sakota E; Asai K; Nakamura Y
Biochimie; 2011 Jul; 93(7):1081-8. PubMed ID: 21524680
[TBL] [Abstract][Full Text] [Related]
16. Where are we heading to in pharmacological IBD therapy?
Rogler G
Pharmacol Res; 2015 Oct; 100():220-7. PubMed ID: 26277232
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory bowel disease therapy: blockade of cytokines and cytokine signaling pathways.
Yamamoto-Furusho JK
Curr Opin Gastroenterol; 2018 Jul; 34(4):187-193. PubMed ID: 29846261
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic strategies for targeting the IL-6/STAT3 cytokine signaling pathway in inflammatory bowel disease.
Mitsuyama K; Matsumoto S; Masuda J; Yamasakii H; Kuwaki K; Takedatsu H; Sata M
Anticancer Res; 2007; 27(6A):3749-56. PubMed ID: 17970038
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease.
Laverny G; Penna G; Vetrano S; Correale C; Nebuloni M; Danese S; Adorini L
Immunol Lett; 2010 Jun; 131(1):49-58. PubMed ID: 20350569
[TBL] [Abstract][Full Text] [Related]
20. [Dynamics of serum IL-17A, IL-17F and IL-23 in patients with inflammatory bowel disease].
Lazebnik LB; Sagynbaeva VÉ; Kniazev OV; Ruchkina IN; Efremov LI
Eksp Klin Gastroenterol; 2011; (11):49-52. PubMed ID: 22629719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
